News

Vir’s hepatitis B combo falls short in Phase II trial
Vir is holding off on advancing the combination therapy to Phase III trials until it secures a development partner.
MyChesCo on MSN2d
Arbutus Biopharma Showcases Promising Results for Hepatitis B Therapies at EASL Congress 2025
Arbutus Biopharma Corporation (Nasdaq: ABUS) recently presented compelling data on its investigational hepatitis B therapies, ...
Rutland Herald2d
Health Talk: Understanding hepatitis
Viral hepatitis is a leading cause of liver disease, liver cancer and liver transplant in the United States and is a focus of an annual national awareness campaign that occurs ...
The Vincennes Sun-Commercial3d
May is Hepatitis Awareness Month: Know the ABCs of viral hepatitis
The Knox County Health Department shared in a press release that each May, the United States observes Hepatitis Awareness Month to bring attention to viral hepatitis and ...
‘My dad would have been devastated’ – bereaved speak out over infected blood payouts.
A nurse whose father died after being given infected blood has said he would have been “disgusted” at the way bereaved ...
The Manila Times4d
SCG Announces Late-Breaking Clinical Data of SCG101 in HBV-Related Hepatocellular Carcinoma Presented at EASL 2025
SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, today announced late-breaking clinical data from ...
Global Survey Reveals Urgent Gaps in Awareness, Access, and Treatment for Hepatitis D
A new report released today by the World Hepatitis Alliance (WHA) reveals widespread knowledge gaps, inequities in access, ...
Liver Disease Treatments Market Research 2025-2030: CAGR of 7.1% Expected with Revenues Reaching US$69.1 Billion by 2030
Industry Giants Gilead Sciences, Bristol Myers Squibb, AbbVie, and Merck & Co. Lead the CompetitionDublin, May 06, 2025 (GLOBE NEWSWIRE) -- The "Liver Disease Treatments Market" report has been added ...